Translating gastric cancer genomics into targeted therapies
نویسندگان
چکیده
منابع مشابه
Translating cancer genomics into clinical oncology.
The medical directors of the organ-procurement organizations can determine the ABO compatibility of the exchange pairs and the proximity of their centers and note the date of the listings. Equipoise should be achieved in terms of the medical characteristics of the donors and recipients; therefore, donors and recipients should be aware of the medical characteristics of their exchange partners, e...
متن کاملTranslating Autoimmune Pathogenesis into Targeted Therapies for Systemic Sclerosis
Targeted therapies including tumour necrosis factor α (TNFα) inhibitors have trans‐ formed the management of a number of autoimmune conditions over the past 20 years. One autoimmune rheumatological condition with significant potential for the develop‐ ment of targeted therapies is systemic sclerosis (SSc). In this chapter, we use SSc as an example of how research into the pathogenic processes u...
متن کاملBeyond histology: translating tumor genotypes into clinically effective targeted therapies.
Increased understanding of intertumoral heterogeneity at the genomic level has led to significant advancements in the treatment of solid tumors. Functional genomic alterations conferring sensitivity to targeted therapies can take many forms, and appropriate methods and tools are needed to detect these alterations. This review provides an update on genetic variability among solid tumors of simil...
متن کاملTranslating Research into Therapies
The human body is more than the sum of its organs. Yet for hundredsof years,medicine andmedical research have divvied up the totality of the person into diseases that are organ specific and characterized largely by their phenotypic presentation. These divisions are also reflected in the organization of academic medical centers and pharmaceutical research and development and even permeate the fu...
متن کاملMetastatic gastric cancer – focus on targeted therapies
Gastric cancer (GC) is currently the second leading cause of cancer death worldwide; unfortunately, most patients will present with locally advanced or metastatic disease. Despite recent progress in diagnosis, surgery, chemotherapy, and radiotherapy, prognosis remains poor. A better understanding of GC biology and signaling pathways is expected to improve GC therapy, and the integration of targ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Critical Reviews in Oncology/Hematology
سال: 2016
ISSN: 1040-8428
DOI: 10.1016/j.critrevonc.2016.02.007